ArticleCureus2024
Pregabalin for Neuropathic Pain in Post-radiotherapy Head and Neck Cancer Patients: A Retrospective Study and Review of the Literature.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Opioid Stewardship and Gastrointestinal (GI)-Sparing Alternatives in Primary Care Pain Management.Cureus · 2025Review
- Neuropathic Pain: A Comprehensive Bibliometric Analysis of Research Trends, Contributions, and Future Directions.Current pain and headache reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHead and neck cancer (HNC) patients may experience neuropathic pain (NP) due to radiotherapy (RT), which may become chronic. Pregabalin, an anticonvulsant, alters the transmission of painful stimuli at the synaptic level, modifying their perception. Pregabalin is used in NP treatment, but limited data exist on RT-treated HNC patients. This retrospective study aimed to present a case series of HNC patients with chronic NP after RT managed with pregabalin.
methodsHNC patients' records from the Department of Oral Medicine and Pathology and Hospital Dentistry, School of Dentistry, National and Kapodistrian University of Athens (NKUA), were searched. Outcome measures were obtained using the Douleur Neuropathique 4 (DN4) scale for NP and the numeric rating scale (NRS) for pain. The use of additional analgesic medication was also recorded.
resultsFive HNC (four oral and one nasopharyngeal cancer) patients (mean age 58.5 years) who had received RT (mean total dose 64.7 gray (Gy)) and developed chronic (i.e., present for at least three months after RT) NP, characterized by a positive DN4 score ≥4, were identified. The initial assessment was five months to six years after RT (mean DN4=4.6±0.89 and mean NRS=6±3.08). "Burning," "pins and needles," and "numbness" were the NP descriptors mostly used. Pregabalin was titrated up to 150-300 mg per day; paracetamol and/or tramadol were also administered (daily doses 3000 mg and 100-150 mg, respectively). A substantial pain relief (≥50%) according to the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) (mean DN4=1.6±1.67 and NRS=1.6±1.67) was reported after two to three months of treatment, when tapering was initiated. Two patients (2/5) had complete remission of symptoms (DN4=0, NRS=0). No serious adverse effects were reported; one patient reported excess salivation.
conclusionsPregabalin may be a promising option for managing RT-related chronic NP in HNC patients. Further studies, including randomized controlled trials on RT-treated HNC patients, should be conducted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.